Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles.

Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X.

Virology. 2011 Feb 20;410(2):345-52. doi: 10.1016/j.virol.2010.11.017. Epub 2010 Dec 23.

2.

Noroviral P particle: structure, function and applications in virus-host interaction.

Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X.

Virology. 2008 Dec 5;382(1):115-23. doi: 10.1016/j.virol.2008.08.047. Epub 2008 Oct 16.

3.

Antigenic and Cryo-Electron Microscopy Structure Analysis of a Chimeric Sapovirus Capsid.

Miyazaki N, Taylor DW, Hansman GS, Murata K.

J Virol. 2015 Dec 23;90(5):2664-75. doi: 10.1128/JVI.02916-15.

4.

Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus.

Koho T, Huhti L, Blazevic V, Nurminen K, Butcher SJ, Laurinmäki P, Kalkkinen N, Rönnholm G, Vesikari T, Hytönen VP, Kulomaa MS.

J Virol Methods. 2012 Jan;179(1):1-7. doi: 10.1016/j.jviromet.2011.05.009. Epub 2011 May 12.

PMID:
21600929
5.

Nanobody binding to a conserved epitope promotes norovirus particle disassembly.

Koromyslova AD, Hansman GS.

J Virol. 2015 Mar;89(5):2718-30. doi: 10.1128/JVI.03176-14. Epub 2014 Dec 17.

6.

Production of Brazilian human norovirus VLPs and comparison of purification methods.

Lamounier TA, de Oliveira LM, de Camargo BR, Rodrigues KB, Noronha EF, Ribeiro BM, Nagata T.

Braz J Microbiol. 2015 Oct-Dec;46(4):1265-8. doi: 10.1590/S1517-838246420140925. Epub 2015 Oct 9.

7.

Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Kocher J, Bui T, Giri-Rachman E, Wen K, Li G, Yang X, Liu F, Tan M, Xia M, Zhong W, Jiang X, Yuan L.

J Virol. 2014 Sep 1;88(17):9728-43. doi: 10.1128/JVI.01249-14. Epub 2014 Jun 11.

8.

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.

10.

Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Kim SH, Chen S, Jiang X, Green KY, Samal SK.

J Virol. 2014 Sep 1;88(17):9718-27. doi: 10.1128/JVI.01570-14. Epub 2014 Jun 11.

11.

Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry.

Bereszczak JZ, Barbu IM, Tan M, Xia M, Jiang X, van Duijn E, Heck AJ.

J Struct Biol. 2012 Feb;177(2):273-82. doi: 10.1016/j.jsb.2012.01.005. Epub 2012 Jan 12.

PMID:
22266117
12.

Establishment of a novel method without sequence modification for developing NoV P particle-based chimeric vaccines.

Li Y, Fu L, Hu Y, Jin H, Zheng Y, Yin Y, Wu H, Yu X, Kong W.

Protein Expr Purif. 2016 May;121:73-80. doi: 10.1016/j.pep.2016.01.003. Epub 2016 Jan 7.

PMID:
26773744
13.
14.
15.

Secreted production of assembled Norovirus virus-like particles from Pichia pastoris.

Tomé-Amat J, Fleischer L, Parker SA, Bardliving CL, Batt CA.

Microb Cell Fact. 2014 Sep 10;13:134. doi: 10.1186/s12934-014-0134-z.

16.

Noroviral p-particles as an in vitro model to assess the interactions of noroviruses with probiotics.

Rubio-del-Campo A, Coll-Marqués JM, Yebra MJ, Buesa J, Pérez-Martínez G, Monedero V, Rodríguez-Díaz J.

PLoS One. 2014 Feb 21;9(2):e89586. doi: 10.1371/journal.pone.0089586. eCollection 2014.

17.

Production of Norovirus VLPs to size homogeneity.

Huo Y, Wan X, Wang Z, Meng S, Shen S.

Virus Res. 2015 Jun 2;204:1-5. doi: 10.1016/j.virusres.2015.04.009. Epub 2015 Apr 17.

PMID:
25892715
18.
19.

Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding.

Allen DJ, Noad R, Samuel D, Gray JJ, Roy P, Iturriza-Gómara M.

Virol J. 2009 Sep 25;6:150. doi: 10.1186/1743-422X-6-150.

20.

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY.

Vaccine. 2012 May 21;30(24):3580-6. doi: 10.1016/j.vaccine.2012.03.050. Epub 2012 Mar 31.

Supplemental Content

Support Center